X

Trial Profile

A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALRN 6924 (Primary) ; Carboplatin; Pemetrexed; Topotecan
Indications Chemotherapy-induced damage; Drug toxicity; Myelosuppression
Focus Adverse reactions; Proof of concept
Sponsors Rein Therapeutics

Most Recent Events

10 Jan 2025 According to Rein Therapeutics media release, Aileron Therapeutics announces rebranding to Rein Therapeutics
09 Oct 2022 This trial has been discontinued in Poland (End Date: 30 Aug 2022) according to European Clinical Trials Database record
07 Oct 2022 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com